Esperion Announces FDA Confirmation of Regulatory Pathway to Approval for the Combination of Bempedoic Acid and Ezetimibe
June 26, 2017 16:05 ET
|
Esperion Therapeutics, Inc.
– Complementary, Non-statin, Oral Bempedoic Acid / Ezetimibe Combination Therapy Demonstrates 48% Lowering of LDL-C and Significant hsCRP Reduction with Potential for Lower Occurrence of...
Esperion Announces FDA Confirmation Regarding Regulatory Pathway to Approval for an LDL-C Lowering Indication for Bempedoic Acid
March 20, 2017 07:30 ET
|
Esperion Therapeutics, Inc.
- Global Pivotal Phase 3 Program Design Can Support Approval for an LDL-C Lowering Indication - - Proposed LDL-C Lowering Indication Will Include Patients with High CVD Risk, Specifically Those...